for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Shanghai Fosun's Unit Hengenix Biotech Plans To Begin Phase I Clinical Trial Of HLX70 In U.S.

Oct 8 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd :

* SAYS ITS UNIT HENGENIX BIOTECH PLANS TO BEGIN PHASE I CLINICAL TRIAL OF HUMAN MONOCLONAL NEUTRALISING ANTIBODY TREATMENT HLX70 IN THE U.S. WHEN CONDITIONS ARE READY Source text in Chinese: bit.ly/3iIgf0S Further company coverage: (Reporting by Hong Kong newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up